Cell Reports· 2026Q1
E2 displacement of CIP2A from TOPBP1 activates the DNA damage response during papillomavirus life cycles
- 3citations
- Q1SCImago
- 2026year
Short summary
Papillomavirus E2 protein displaces CIP2A from TOPBP1, leading to CIP2A inhibition of PP2A, ATM-mediated DNA damage response (DDR) activation, and enhanced viral replication.
AI-generated from the title and abstract; the full text is not read.
Key points
- Papillomavirus E2 protein activates the DNA damage response (DDR) by displacing CIP2A from TOPBP1.
- CIP2A inhibition of PP2A leads to ATM-mediated DDR activation.
- The DDR promotes viral replication by favoring an 'ATM up, ATR down' signaling state.
- ATM inhibition selectively kills E2-expressing cells, indicating a potential therapeutic target.
AI-generated from the title and abstract; the full text is not read.
Abstract
The papillomavirus life cycle is intricately linked to epithelial differentiation, and the virus manipulates the differentiation process to facilitate viral production. One such manipulation is activation of the DNA damage response (DDR) which promotes viral replication via homologous recombination. This report demonstrates that the papillomavirus transcription/replication/segregation factor E2 activates the DNA damage response (DDR). During differentiation, E2 displacement of CIP2A from TOPBP1 causes CIP2A to bind and inhibit PP2A resulting in DDR activation via ATM phosphorylation. The DDR promotes inhibitory interaction of DBC1 with the class III deacetylase SIRT1, which further boosts the DDR via increased acetylation and stability of viral and host proteins. E2 forms a complex with TOPBP1 and ATM, while preventing ATR activation by blocking TOPBP1-ATR interaction. This "ATM up ATR down" phenotype promotes viral replication via ATM promotion of homologous recombination, and cell proliferation via inhibition of ATR. We demonstrate this mechanism of DDR activation in multiple systems: keratinocytes expressing only E2, in foreskin keratinocytes immortalized by HPV16, in HPV16 positive keratinocytes derived from a cervical lesion, in pre-neoplastic lesions induced by mouse papillomavirus MmuPV1, in head and neck cancer cell lines that retain E2 expression, and in HPV16 positive oropharyngeal patient derived xenografts that retain E2 expression. ATM inhibition preferentially killed cells expressing E2, presenting a novel strategy for treating HPV early preneoplasia and a large subset of HPV+ oropharyngeal cancers retaining E2 expression and episomal genomes.
The authors' abstract, as published at the source. Cell Reports, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Epidemiology
EpidemiologyMedicine